Phase 1 adaptive dose‐finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high‐risk extremity and trunk soft tissue sarcoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|20|3659-3667

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.20, 2015-10, pp. : 3659-3667

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography

By  

Oncology Research and Treatment, Vol. 31, Iss. 3, 2008-02 ,pp. : 107-112

Karger

Access to resources Recommend Favorite

UVA1 Therapy Dose-Finding Study in Patients with Acute Exacerbated Atopic Dermatitis

By  

International Archives of Allergy and Immunology, Vol. 124, Iss. 1-3, 2012-01 ,pp. : 386-388

Karger

Access to resources Recommend Favorite

Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 50-54

Karger

Access to resources Recommend Favorite

Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 2, 2015-02 ,pp. : 152-157

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic significance of treatment‐induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy

By  

CANCER, Vol. 120, Iss. 23, 2014-12 ,pp. : 3676-3682

John Wiley & Sons Inc

Access to resources Recommend Favorite